The present invention relates to antigenic proteins derived from White Spot Syndrome virus having an estimated size of 19 kDa (VP 19) or 13 kDA (VP13), to the use of these proteins in vaccines and to vaccines on the basis of these proteins. Furthermore, the invention relates to antibodies against these proteins and to the use of antibodies in vaccines, to nucleic acid sequences encoding these proteins and to their use in vaccines. Also, the invention relates to the use of said proteins in the manufacture of a vaccine for prophylaxis and/or treatment of White Spot Syndrome in crustaceans, to vector vaccines and to diagnostic kits comprising said nuclei acids or antibodies.